Karanbir S. Pahil

Karanbir S. Pahil

Auto-generated profile, based on publicly available information

Karanbir S. Pahil

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Nature
Verified
Journal Article
Open access
PDF file
CZClaudia Zampaloni
Claudia Zampaloni
PMPatrizio Mattei
Patrizio Mattei
KBKonrad Bleicher
Konrad Bleicher
LWLotte Winther
Lotte Winther
CTClaudia Thäte
Claudia Thäte
KBKenneth A. Bradley
Kenneth A. Bradley
Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.

3 January 2024 in Nature
Verified
Journal Article
Open access
PDF file
KPKaranbir S. Pahil
Karanbir S. Pahil
MGMorgan S. A. Gilman
Morgan S. A. Gilman
VBVadim Baidin
Vadim Baidin
TCThomas Clairfeuille
Thomas Clairfeuille
PMPatrizio Mattei
Patrizio Mattei
DKDaniel Kahne
Daniel Kahne
Gram-negative bacteria are extraordinarily difficult to kill because their cytoplasmic membrane is surrounded by an outer membrane that blocks the entry of most antibiotics. The impenetrable nature of the outer membrane is due to the presence of a large, amphipathic glycolipid called lipopolysaccharide (LPS) in its outer leaflet1. Assembly of the outer membrane requires transport of LPS across a protein bridge that spans from the cytoplasmic membrane to the cell surface. Maintaining outer membrane integrity is essential for bacterial cell viability, and its disruption can increase susceptibility to other antibiotics2–6. Thus, inhibitors of the seven lipopolysaccharide transport (Lpt) proteins that form this transenvelope transporter have long been sought7–9. A new class of antibiotics that targets the LPS transport machine in Acinetobacter was recently identified. Here, using structural, biochemical and genetic approaches, we show that these antibiotics trap a substrate-bound conformation of the LPS transporter that stalls this machine. The inhibitors accomplish this by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. Collectively, our findings identify an unusual mechanism of lipid transport inhibition, reveal a druggable conformation of the Lpt transporter and provide the foundation for extending this class of antibiotics to other Gram-negative pathogens.

20 March 2019 in Nature
Verified
Journal Article
Closed access
PDF file
TOTristan W. Owens
Tristan W. Owens
RTRebecca J. Taylor
Rebecca J. Taylor
KPKaranbir S. Pahil
Karanbir S. Pahil
BBBlake R. Bertani
Blake R. Bertani
NRNatividad Ruiz
Natividad Ruiz
DKDaniel Kahne
Daniel Kahne

7 May 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GZGe Zhang
Ge Zhang
VBVadim Baidin
Vadim Baidin
KPKaranbir S. Pahil
Karanbir S. Pahil
EMEileen Moison
Eileen Moison
DTDavid Tomasek
David Tomasek
DKDaniel Kahne
Daniel Kahne
New drugs are needed to treat gram-negative bacterial infections. These bacteria are protected by an outer membrane which prevents many antibiotics from reaching their cellular targets. The outer leaflet of the outer membrane contains LPS, which is responsible for creating this permeability barrier. Interfering with LPS biogenesis affects bacterial viability. We developed a cell-based screen that identifies inhibitors of LPS biosynthesis and transport by exploiting the nonessentiality of this pathway in Acinetobacter. We used this screen to find an inhibitor of MsbA, an ATP-dependent flippase that translocates LPS across the inner membrane. Treatment with the inhibitor caused mislocalization of LPS to the cell interior. The discovery of an MsbA inhibitor, which is universally conserved in all gram-negative bacteria, validates MsbA as an antibacterial target. Because our cell-based screen reports on the function of the entire LPS biogenesis pathway, it could be used to identify compounds that inhibit other targets in the pathway, which can provide insights into vulnerabilities of the gram-negative cell envelope. Significance The outer membrane of gram-negative bacteria contains LPS on the cell surface. The presence of LPS creates an effective permeability barrier that protects gram-negative bacteria from small hydrophobic molecules. Because the entire LPS biogenesis pathway, including biosynthesis and transport, is highly conserved, proteins involved are attractive targets for antibiotic discovery. Historically, it has been challenging to target LPS biogenesis since many of the components are membrane proteins with hard-to-assay activities. Utilizing the nonessentiality of this pathway in a gram-negative pathogen, we developed a cell-based screen specific to LPS biogenesis. We identified a small-molecule inhibitor targeting an essential component of the pathway, MsbA, and validated it as an antibacterial target using a combination of genetics, biochemistry, and cellular assays.

10 May 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MMMichael D. Mandler
Michael D. Mandler
VBVadim Baidin
Vadim Baidin
JLJames Lee
James Lee
KPKaranbir S. Pahil
Karanbir S. Pahil
TOTristan W. Owens
Tristan W. Owens
DKDaniel Kahne
Daniel Kahne

27 August 2019 in mBio
Verified
Journal Article
Open access
BSBrent W. Simpson
Brent W. Simpson
KPKaranbir S. Pahil
Karanbir S. Pahil
TOTristan W. Owens
Tristan W. Owens
ELEmily A. Lundstedt
Emily A. Lundstedt
RDRebecca M. Davis
Rebecca M. Davis
NRNatividad Ruiz
Natividad Ruiz
Gram-negative bacteria are naturally resistant to many antibiotics because their surface is covered by the glycolipid LPS. Newly synthesized LPS is transported across the cell envelope by the multiprotein Lpt machinery, which includes LptB 2 FGC, an unusual ABC transporter that extracts LPS from the inner membrane. Like in other ABC transporters, the LptB 2 FGC transport cycle is driven by the cyclical conformational changes that a cytoplasmic, dimeric ATPase, LptB, undergoes when binding and hydrolyzing ATP. How these conformational changes are controlled in ABC transporters is poorly understood. Here, we identified two lethal changes in LptB that, when combined, remarkably restore wild-type transport function. Biochemical studies revealed that the two changes affect different steps in the transport cycle, having opposing, lethal effects on LptB’s dimerization cycle. Our work provides mechanistic details about the LptB 2 FGC extractor that could be used to develop Lpt inhibitors that would overcome the innate antibiotic resistance of Gram-negative bacteria.